Biopharmaceutical firm Palatin Technologies has outlined a refined strategic direction following its second-quarter financial report. The company is intensifying its commitment to developing treatments for rare forms of obesity. A key question for investors is whether its current financial resources are sufficient to meet its ambitious clinical development goals.
Financial Performance and Runway
For the quarter ended December 31, Palatin posted a net loss of $7.3 million, or $2.86 per share. This compares to a loss of $2.4 million, or $5.92 per share, in the same period the prior year. Notably, the company recorded its first meaningful revenue of $116,000, stemming from cost reimbursements under its collaboration with Boehringer Ingelheim.
Management reported a stabilized liquidity position. As of December 31, Palatin held cash and equivalents of $14.5 million. According to the company, these funds are expected to finance operations through and beyond the first quarter of 2027.
Clinical Pipeline Centered on MC4R
The core of Palatin’s operational strategy now revolves around its Melanocortin-4 Receptor (MC4R) programs. These initiatives target neuroendocrine disorders, including Prader-Willi Syndrome. The company is preparing to file an Investigational New Drug (IND) application for its oral drug candidate, PL7737, in the first half of 2026, with plans to initiate a Phase 1 study thereafter.
Should investors sell immediately? Or is it worth buying Palatin?
A second IND submission is scheduled for the latter half of 2026, this time for a selective peptide MC4R agonist designed for weekly administration. In a complementary move, Palatin executed a sublicense agreement for the compound PL9643 in January. This transaction resulted in the cancellation of $3.8 million in debt, which will be recognized as license revenue in the current quarter.
Capital Raise and Relisting
Palatin bolstered its balance sheet in November through a public offering that raised gross proceeds of $18.2 million. This capital infusion was instrumental in allowing the company to regain compliance with the listing requirements of the NYSE American exchange. Its shares have since resumed normal trading under the ticker symbol “PTN.”
The company’s upcoming operational milestones are contingent on the timely submission of its IND applications. Palatin is scheduled to release its third-quarter financial results on May 9, 2026.
Ad
Palatin Stock: Buy or Sell?! New Palatin Analysis from February 20 delivers the answer:
The latest Palatin figures speak for themselves: Urgent action needed for Palatin investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 20.
Palatin: Buy or sell? Read more here...
